Thyme Care completed a $97 million Series D funding round featuring major investors such as CVS Health Ventures, Foresite Capital, and Humana. The company focuses on delivering value-based care models for cancer patients, integrating digital health tools to personalize and optimize oncology treatment pathways. Total capital raised now exceeds $275 million, reinforcing confidence in tech-driven cancer care transformation.